Immune checkpoint inhibitors block binding of tolerogenic ligands CTLA-4 and PD-1 to their cognate receptors, and therefore promote the activity of host anti-tumor T cells silenced by tumor activation of these pathways. The gene discussed is CTLA4; the disease is neoplasm.